戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tigen that is strongly expressed by leukemic hairy cells.
2 1c promoter to levels equivalent to those in hairy cells.
3 hat it is sufficient to direct expression in hairy cells.
4 ith residual marrow disease (1% to 5% marrow hairy cells), and 2 (13%) had a partial response.
5                                              Hairy cells are clonal expansions of mature, activated B
6                                              Hairy cells are highly activated clonal B cells related
7 repared from other cell types indicated that hairy cells exhibit abnormal constitutive expression of
8 sent study was to address these issues using hairy cells (HCs) and chronic lymphocytic leukemia cells
9 ossible receptor-ligand interactions between hairy cells (HCs) and ECs were examined and a central im
10                                              Hairy cells (HCs) are mature malignant B cells that cont
11                       One unusual feature of hairy cells (HCs) is the frequent expression of multiple
12 ellular signal-regulated kinase (ERK) in the hairy cells (HCs) of hairy cell leukemia.
13                                          The hairy cells (HCs) of hairy-cell leukemia are intrinsical
14 examine the effects of IFN-alpha on cultured hairy cells (HCs), taking into account the possible modi
15 ete response (CR), defined as presence of no hairy cells in BM and blood with normalization of counts
16 r signal-regulated kinase phosphorylation of hairy cells in vivo.
17 eukaemia is reviewed, focussing first on the hairy cell itself and then on its interactions with the
18 , the 10-year ASRS in Europe was highest for hairy cell leukaemia (82.6% [95% CI 78.9-86.5) and Hodgk
19                               The biology of hairy-cell leukaemia is reviewed, focussing first on the
20 arge fraction of melanomas, thyroid cancers, hairy cell leukaemias and, to a smaller extent, a wide s
21 ia (29), T-cell prolymphocytic leukemia (3), hairy cell leukemia (1), adult T-cell leukemia/lymphoma
22 n bone marrow core biopsies of patients with hairy cell leukemia (HCL) after treatment with 2-chlorod
23 s, 28 low grade B-cell lymphomas, 4 cases of hairy cell leukemia (HCL) and 3 plasmacytomas.
24  V600E mutation was reported in all cases of hairy cell leukemia (HCL) but not in other peripheral B-
25  BRAFV600E mutation was recently detected in hairy cell leukemia (HCL) by whole exome sequencing.
26 tic leukemia (CLL) cases, 100% (32 of 32) of hairy cell leukemia (HCL) cases, 15% (5 of 34) of mantle
27                                              Hairy cell leukemia (HCL) derives from a mature B cell a
28  has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 years.
29       The discovery of effective therapy for hairy cell leukemia (HCL) has increased the relevance of
30                                              Hairy cell leukemia (HCL) is a chronic B-cell leukemia n
31                                              Hairy cell leukemia (HCL) is a chronic lymphoproliferati
32                                              Hairy cell leukemia (HCL) is a chronic mature B-cell neo
33                                              Hairy cell leukemia (HCL) is a distinct clinicopathologi
34                                              Hairy cell leukemia (HCL) is a distinct clinicopathologi
35                                              Hairy cell leukemia (HCL) is a rare B-cell malignancy, a
36                                              Hairy cell leukemia (HCL) is a rare, indolent B-cell dis
37                                              Hairy cell leukemia (HCL) is an indolent B-cell neoplasm
38                                              Hairy cell leukemia (HCL) is an uncommon, indolent, chro
39                                              Hairy cell leukemia (HCL) is characterized by underexpre
40                      Cladribine treatment of hairy cell leukemia (HCL) is complicated by neutropenic
41                                              Hairy cell leukemia (HCL) is marked by near 100% mutatio
42                                          One hairy cell leukemia (HCL) patient achieved a complete re
43                                              Hairy cell leukemia (HCL) responds very well to frontlin
44                                              Hairy cell leukemia (HCL) shows unique clinicopathologic
45 iral oncogene homolog B1 (BRAF) mutations in hairy cell leukemia (HCL) subsets, demonstrating that BR
46                                   To compare hairy cell leukemia (HCL) with chronic lymphocytic leuke
47 produce high response rates in patients with hairy cell leukemia (HCL), a significant number of patie
48 ), 7 of 7 follicular lymphoma (FL), 13 of 17 hairy cell leukemia (HCL), and 2 of 3 mantle cell lympho
49 ch as chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL), are associated with myelosupp
50  target on B-cell malignancies, particularly hairy cell leukemia (HCL), but its soluble extracellular
51 sions (CRs) in the majority of patients with hairy cell leukemia (HCL), neither the actual relapse ra
52       These included Hodgkin's disease (HD), hairy cell leukemia (HCL), non-Hodgkin's lymphoma (NHL),
53 e (BRAF V600E) is the key driver mutation in hairy cell leukemia (HCL), suggesting opportunities for
54                                  However, in hairy cell leukemia (HCL), these processes are particula
55  defining the BRAF-V600E driving mutation in hairy cell leukemia (HCL),provide extensive laboratory s
56 600E is the key oncogenic driver mutation in hairy cell leukemia (HCL).
57 ious CDKN1B mutation in 16% of patients with hairy cell leukemia (HCL).
58  recently described as a molecular marker of hairy cell leukemia (HCL).
59 duces protracted remissions in patients with hairy cell leukemia (HCL).
60 nd also occurs in the hematopoietic neoplasm hairy cell leukemia (HCL).
61  accepted as the agent of choice in treating hairy cell leukemia (HCL).
62 tibody, rituximab, in relapsed or refractory hairy cell leukemia (HCL).
63 ates when used as first-line monotherapy for hairy cell leukemia (HCL); however, patients continue to
64  low-grade follicular lymphoma (FL; n = 44), hairy cell leukemia (HCL; n = 15), and reactive lymphoid
65 glioma (n = 13), high-grade glioma (n = 45), hairy cell leukemia (n = 55) and multiple myeloma (n = 1
66 cally, this paper describes the frequency of hairy cell leukemia among all adult leukemias and charac
67 ons is helpful in the diagnosis of classical hairy cell leukemia and a number of histiocytic neoplasm
68  marker of disease activity in patients with hairy cell leukemia and adult T-cell leukemia/lymphoma.
69     Immunotoxin therapy is very effective in hairy cell leukemia and also has activity in other hemol
70 h an immunophenotype consistent with classic hairy cell leukemia and BRAF mutations other than just V
71 cladribine) is effective in the treatment of hairy cell leukemia and chronic lymphocytic leukemia.
72 lymphoid neoplasm subtypes, most notably for hairy cell leukemia and follicular lymphoma, black predo
73 ate of complete remissions in drug-resistant hairy cell leukemia and has a lower response rate in ped
74       RITs have shown efficacy in refractory hairy cell leukemia and in some children with acute lymp
75  with reports of only a few cases of variant hairy cell leukemia and neurological disease associated
76 ladribine is best known for the treatment of hairy cell leukemia and other lymphoid cancers, it also
77   The primary objective in multiply-relapsed hairy cell leukemia and variant (HCL/HCLv) was to determ
78                           The description of hairy cell leukemia as a specific clinical entity was pu
79 issions in most patients with drug-resistant hairy cell leukemia but had less activity in leukemias w
80        HA22 is very active in drug-resistant hairy cell leukemia but is less active in children with
81  V600E-expressing human primary melanoma and hairy cell leukemia cells.
82                                          The Hairy Cell Leukemia Foundation convened an international
83 ibine followed by rituximab in patients with hairy cell leukemia including the vari-ant form (HCLv).
84                                              Hairy cell leukemia is a chronic B-cell disorder that fo
85                                              Hairy cell leukemia is an indolent, chronic B-cell lymph
86                                              Hairy cell leukemia is an uncommon hematologic malignanc
87                                     Although hairy cell leukemia is uniquely sensitive to interferon-
88 N-alpha2b were approved for the treatment of hairy cell leukemia just 11 years ago.
89        Enormous progress in the treatment of hairy cell leukemia over the last five decades has emerg
90                                 Treatment of hairy cell leukemia should be considered for symptomatic
91         Immunophenotypic features in classic hairy cell leukemia show that the leukemic cells express
92 entostatin is a highly effective regimen for hairy cell leukemia that produces durable complete respo
93 utcome of young patients with a diagnosis of hairy cell leukemia treated with cladribine.
94                                              Hairy cell leukemia variant (HCLv) presents with high di
95                 A total of 358 patients with hairy cell leukemia were treated with cladribine at 0.08
96 notoxin treatment and report that samples of hairy cell leukemia with high levels of Bim protein resp
97 relapse-free survival times in patients with hairy cell leukemia, a disease that historically had bee
98 ancies including cutaneous T-cell lymphomas, hairy cell leukemia, and diffuse large B-cell lymphomas.
99 ity against chronic lymphocytic leukemia and hairy cell leukemia, in general, monoclonal antibodies h
100 , an immunotoxin with impressive activity in hairy cell leukemia, is in phase II trials in CLL as wel
101 al blood samples obtained from patients with hairy cell leukemia, marginal zone lymphoma, and chronic
102 lymphoma, CLL, acute lymphoblastic leukemia, hairy cell leukemia, non-Hodgkin lymphoma (including rit
103 splenomegaly, constitutional symptoms due to hairy cell leukemia, or recurrent serious infections.
104 d many complete remissions in drug-resistant Hairy cell leukemia, where many treatment cycles can be
105 ts profound impact on the natural history of hairy cell leukemia, with responses approaching 100% and
106       Only 2 of 40 deaths were attributed to hairy cell leukemia.
107 denosine analog, is clinically effective for hairy cell leukemia.
108 y profile when administered to patients with hairy cell leukemia.
109 ents with either relapsed classic or variant hairy cell leukemia.
110 time the clinical and pathologic features of hairy cell leukemia.
111 1 in both leukemia and lymphoma, and BRAF in hairy cell leukemia.
112 ll known and revolutionized the treatment of hairy cell leukemia.
113  signaling important for the pathogenesis of hairy cell leukemia.
114 ted kinase (ERK) in the hairy cells (HCs) of hairy cell leukemia.
115 mphomas with villous lymphocytes (SLVLs) and hairy cell leukemia.
116                                              Hairy-cell leukemia (HCL) is a CD20+ indolent B-cell can
117 e been used to treat many diseases including hairy-cell leukemia and hepatitis B and C and have also
118 CldAdo), which is the drug of choice against hairy-cell leukemia and other neoplasms, from 2'-deoxygu
119                     The hairy cells (HCs) of hairy-cell leukemia are intrinsically activated mature c
120  BRAF inhibitor vemurafenib in patients with hairy-cell leukemia that had relapsed after treatment wi
121  induce complete remissions in patients with hairy-cell leukemia that is resistant to treatment with
122                                              Hairy-cell leukemia that is resistant to treatment with
123 d many complete remissions in drug-resistant hairy-cell leukemia when several cycles of the agent can
124 B-Raf kinase (BRAF mutations) are present in hairy-cell leukemia, cutaneous melanoma, thyroid carcino
125  BRAF V600E is the genetic lesion underlying hairy-cell leukemia.
126 tive in patients with relapsed or refractory hairy-cell leukemia.
127 isms driving variant and IGHV4-34-expressing hairy-cell leukemias, we performed whole-exome sequencin
128                          Furthermore, in the hairy cell line EH, inhibition of Ras signaling through
129                            The activation of hairy cells makes them unusually sensitive to interferon
130                                              Hairy cells possess clonal immunoglobulin gene rearrange
131   Functional inhibition of AP-1 expressed by hairy cells reduced CD11c promoter activity by 80%.
132 Comparison of nuclear extracts prepared from hairy cells with those prepared from other cell types in

 
Page Top